Asia Pacific Thrombosis And Hemostasis Biomarkers Market Size & Outlook
Related Markets
Asia Pacific thrombosis and hemostasis biomarkers market highlights
- The Asia Pacific thrombosis and hemostasis biomarkers market generated a revenue of USD 1,108.7 million in 2022.
- The market is expected to grow at a CAGR of 7.4% from 2023 to 2030.
- In terms of segment, reagents & consumables was the largest revenue generating product in 2022.
- Reagents & Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 1,108.7 million |
| Market revenue in 2030 | USD 1,967.7 million |
| Growth rate | 7.4% (CAGR from 2022 to 2030) |
| Largest segment | Reagents & consumables |
| Fastest growing segment | Reagents & Consumables |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Analyzers, Reagents & Consumables |
| Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.1% of the global thrombosis and hemostasis biomarkers market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,967.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Thrombosis And Hemostasis Biomarkers Market Scope
Thrombosis And Hemostasis Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Diazyme Laboratories | View profile | 51-100 | Poway, California, United States, North America | http://www.diazyme.com/ |
| Biomedica Diagnostics | View profile | 11-50 | Windsor, Ontario, Canada, North America | https://biomedicadiagnostics.com |
| Werfen | View profile | 5001-10000 | Barcelona, Catalonia, Spain, Europe | http://www.werfen.com/ |
| Horiba Ltd | View profile | 8665 | 2, Miyanohigashi-cho, Kisshoin, Minami-ku, Kyoto, Japan, 601-8510 | http://www.horiba.co.jp |
| QuidelOrtho Corp | View profile | 7100 | 9975 Summers Ridge Road, San Diego, CA, United States, 92121 | https://www.quidelortho.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Siemens Healthineers AG ADR | View profile | 71400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | https://www.siemens-healthineers.com |
| BioMerieux SA | View profile | 13982 | Marcy l’Etoile, Lyon, France, 69280 | http://www.biomerieux.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
Asia Pacific thrombosis and hemostasis biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.26% in 2022. Horizon Databook has segmented the Asia Pacific thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness significant growth due to the local presence of leading thrombosis and hemostasis biomarker companies and an increase in R&D investment. There has been an increase in R&D investments in China, India, and Japan, which has accelerated the development of thrombosis and hemostasis biomarkers.
In addition, there has been an increase in the population and disposable income in developing countries such as India, Japan, and China. Growing geriatric population susceptible to diseases and rising prevalence of target diseases, such as cardiovascular diseases and blood clotting disorders, are anticipated to propel the Asia Pacific market over the coming years.
For instance, according to research published in ScienceDirect, there were 18.6 million CVD deaths globally in 2019, of which, 58% occurred in Asia Pacific. Diverse reimbursement policies in Asia Pacific for biomarker testing are influencing the market in the region.
Reasons to subscribe to Asia Pacific thrombosis and hemostasis biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific thrombosis and hemostasis biomarkers market databook
-
Our clientele includes a mix of thrombosis and hemostasis biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific thrombosis and hemostasis biomarkers market size, by country, 2018-2030 (US$M)
Asia Pacific Thrombosis And Hemostasis Biomarkers Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
